Wednesday, October 18, 2017

MissionIRNewsBreaks – India Globalization Capital, Inc. (NYSE: IGC) Approaching Commercialization of IGC-AD1 in Early 2018

India Globalization Capital, Inc. (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, this morning provided compelling in vitro data compiled from genetically engineered cell lines within an Alzheimer’s disease model showing that, at varying concentrations of IGC-AD1, the expression of GSK3β is reduced by as much as 62 percent. “Based on this and other previously announced compelling data, we are readying IGC-AD1, brand name Hyalolex, in a liquid formulation for commercialization in early 2018,” Ram Mukunda, CEO of IGC, stated in the news release. “We have identified Germany, Canada and certain licensed medical cannabis states in the U.S. for commercialization… Our initial research indicates that there are about 7.8 million patients with AD in these combined markets.” The newly-announced results, when combined with earlier reported data showing that IGC-AD1 reduces Aβ production and inhibits Aβ aggregation without any neuronal toxicity, represent a novel breakthrough toward the treatment of Alzheimer’s, which is known as America’s most expensive disease with an estimated annual cost to the U.S. economy of $236 billion.

To view the full press release, visit http://dtn.fm/vc40E

About IGC

IGC is engaged in the development of cannabis based combination therapies to treat Alzheimer’s, pain, nausea, eating disorders, several end points of Parkinson’s, and epilepsy in dogs and cats. IGC has assembled a portfolio of patent filings and four lead product candidates addressing these conditions. The company is based in Maryland, USA. For more information visit www.igcinc.us

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html